Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.

Safety and immunogenicity of a live attenuated RSV vaccine in healthy RSV-seronegative children 5 to 24 months of age.

Despite substantial morbidity associated with respiratory syncytial virus (RSV) infection, there is no licensed vaccine. MEDI-559 is a live attenuated intranasal vaccine candidate being developed for prevention of lower respiratory illness due to RSV in young children. This randomized, placebo-contr...

Full description

Bibliographic Details
Main Authors: Elissa Malkin, Ram Yogev, Nazha Abughali, Joseph Sliman, C Kathy Wang, Fengrong Zuo, Chin-Fen Yang, Mark Eickhoff, Mark T Esser, Roderick S Tang, Filip Dubovsky
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3812203?pdf=render

Internet

http://europepmc.org/articles/PMC3812203?pdf=render

Similar Items